Hillstar Bio | $67,000,000 | (Apr 2, 2025)
Sympera AI | $10,000,000 | (Apr 2, 2025)
LTV.ai | $5,200,000 | (Apr 2, 2025)
MimiVax, LLC
United States
- Buffalo, NY
- 10/12/2021
- Unknown
- $5,000,000
Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates
MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer.
SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2 clinical trial in adults with newly diagnosed glioblastoma. Additional indications are being evaluated through Phase 1 clinical trials in multiple myeloma combination with REVLIMID® (lenalidomide) as well as Phase 1 in Neuro-Endocrine Tumors (NET)
- Industry Pharmaceutical Manufacturing
- Website https://www.mimivax.com/
- LinkedIn https://www.linkedin.com/company/mimivax-llc/
Related People
Michael CiesielskiFounder
United States -
Buffalo-Niagara Falls Area
At MimiVax, our mission is to disrupt cancer. To increase survival and send hope through the development of highly innovative immunotherapies aimed at improving patient's lives.
Sturdy | $6,000,000 | (Apr 2, 2025)
Tomorro | $26,995,875 | (Apr 2, 2025)
voize | $9,000,000 | (Apr 2, 2025)
EVident Battery, Inc. | $3,200,000 | (Apr 2, 2025)
Notable Systems | $12,000,000 | (Apr 2, 2025)
LightSource | $33,000,000 | (Apr 2, 2025)
Atomic(US) | $10,000,000 | (Apr 2, 2025)
ControlTheory | $5,000,000 | (Apr 2, 2025)
Marit Health | $3,200,000 | (Apr 1, 2025)